Selected research
Industry Growth & Trends
Global Drugs for Asthma and COPD Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Drugs for Asthma and COPD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Drugs for Asthma and COPD is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Drugs for Asthma and COPD is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Drugs for Asthma and COPD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Drugs for Asthma and COPD market include GSK, Teva, Novartis, Merck, Mylan, Roche, AstraZeneca, Vertex and Sumitomo Dainippon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Drugs for Asthma and COPD market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Drugs for Asthma and COPD market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Asthma and COPD market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Asthma and COPD.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Drugs for Asthma and COPD market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Drugs for Asthma and COPD Market by Company
GSK
Teva
Novartis
Merck
Mylan
Roche
AstraZeneca
Vertex
Sumitomo Dainippon
Chiesi
Boehringer Ingelheim
Beximco
Drugs for Asthma and COPD Segment by Type
Inhalable & Nasal Spray
Oral
Others
Drugs for Asthma and COPD Segment by Application
Asthma
COPD
Drugs for Asthma and COPD Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Asthma and COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Asthma and COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Asthma and COPD.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Drugs for Asthma and COPD companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Inhalable & Nasal Spray
- Oral
- Others
Applications
- Asthma
- COPD
Companies covered
- GSK
- Teva
- Novartis
- Merck
- Mylan
- Roche
- AstraZeneca
- Vertex
- Sumitomo Dainippon
- Chiesi
- Boehringer Ingelheim
- Beximco
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Drugs for Asthma and COPD Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Drugs for Asthma and COPD Market Size by Region (2021-2032)
- 1.4.1 Global Drugs for Asthma and COPD Market Size by Region (2021-2026)
- 1.4.2 Global Drugs for Asthma and COPD Market Size by Region (2027-2032)
- 1.5 Key Regions Drugs for Asthma and COPD Market Size (2021-2032)
- 1.5.1 North America Drugs for Asthma and COPD Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Drugs for Asthma and COPD Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Drugs for Asthma and COPD Market Size Growth Rate (2021-2032)
- 1.5.4 South America Drugs for Asthma and COPD Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Drugs for Asthma and COPD Market Size Growth Rate (2021-2032)
2 Drugs for Asthma and COPD Market by Type
- 2.1 Type Introduction
- 2.1.1 Inhalable & Nasal Spray
- 2.1.2 Oral
- 2.1.3 Others
- 2.2 Global Drugs for Asthma and COPD Market Size by Type
- 2.2.1 Global Drugs for Asthma and COPD Market Size Overview by Type (2021-2032)
- 2.2.2 Global Drugs for Asthma and COPD Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Drugs for Asthma and COPD Market Size Forecasted by Type (2027-2032)
- 2.3 Global Drugs for Asthma and COPD Market Size by Regions
- 2.3.1 North America Drugs for Asthma and COPD Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Drugs for Asthma and COPD Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Drugs for Asthma and COPD Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Drugs for Asthma and COPD Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Drugs for Asthma and COPD Market Size Breakdown by Type (2021-2026)
3 Drugs for Asthma and COPD Market by Application
- 3.1 Type Introduction
- 3.1.1 Asthma
- 3.1.2 COPD
- 3.2 Global Drugs for Asthma and COPD Market Size by Application
- 3.2.1 Global Drugs for Asthma and COPD Market Size Overview by Application (2021-2032)
- 3.2.2 Global Drugs for Asthma and COPD Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Drugs for Asthma and COPD Market Size Forecasted by Application (2027-2032)
- 3.3 Global Drugs for Asthma and COPD Market Size by Regions
- 3.3.1 North America Drugs for Asthma and COPD Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Drugs for Asthma and COPD Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Drugs for Asthma and COPD Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Drugs for Asthma and COPD Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Drugs for Asthma and COPD Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Drugs for Asthma and COPD Industry Trends
- 4.2 Drugs for Asthma and COPD Industry Drivers
- 4.3 Drugs for Asthma and COPD Industry Opportunities and Challenges
- 4.4 Drugs for Asthma and COPD Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Drugs for Asthma and COPD Revenue (2021-2026)
- 5.2 Global Drugs for Asthma and COPD Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Drugs for Asthma and COPD Key Company Headquarters & Area Served
- 5.4 Global Drugs for Asthma and COPD Company, Product Type & Application
- 5.5 Global Drugs for Asthma and COPD Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Drugs for Asthma and COPD Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Drugs for Asthma and COPD Players Market Share by Revenue in 2025
- 5.6.3 2025 Drugs for Asthma and COPD Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 GSK
- 6.1.1 GSK Company Information
- 6.1.2 GSK Business Overview
- 6.1.3 GSK Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 GSK Drugs for Asthma and COPD Product Portfolio
- 6.1.5 GSK Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Teva Drugs for Asthma and COPD Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis Drugs for Asthma and COPD Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Merck
- 6.4.1 Merck Company Information
- 6.4.2 Merck Business Overview
- 6.4.3 Merck Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Merck Drugs for Asthma and COPD Product Portfolio
- 6.4.5 Merck Recent Developments
- 6.5 Mylan
- 6.5.1 Mylan Company Information
- 6.5.2 Mylan Business Overview
- 6.5.3 Mylan Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Mylan Drugs for Asthma and COPD Product Portfolio
- 6.5.5 Mylan Recent Developments
- 6.6 Roche
- 6.6.1 Roche Company Information
- 6.6.2 Roche Business Overview
- 6.6.3 Roche Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Roche Drugs for Asthma and COPD Product Portfolio
- 6.6.5 Roche Recent Developments
- 6.7 AstraZeneca
- 6.7.1 AstraZeneca Company Information
- 6.7.2 AstraZeneca Business Overview
- 6.7.3 AstraZeneca Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 AstraZeneca Drugs for Asthma and COPD Product Portfolio
- 6.7.5 AstraZeneca Recent Developments
- 6.8 Vertex
- 6.8.1 Vertex Company Information
- 6.8.2 Vertex Business Overview
- 6.8.3 Vertex Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Vertex Drugs for Asthma and COPD Product Portfolio
- 6.8.5 Vertex Recent Developments
- 6.9 Sumitomo Dainippon
- 6.9.1 Sumitomo Dainippon Company Information
- 6.9.2 Sumitomo Dainippon Business Overview
- 6.9.3 Sumitomo Dainippon Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Sumitomo Dainippon Drugs for Asthma and COPD Product Portfolio
- 6.9.5 Sumitomo Dainippon Recent Developments
- 6.10 Chiesi
- 6.10.1 Chiesi Company Information
- 6.10.2 Chiesi Business Overview
- 6.10.3 Chiesi Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Chiesi Drugs for Asthma and COPD Product Portfolio
- 6.10.5 Chiesi Recent Developments
- 6.11 Boehringer Ingelheim
- 6.11.1 Boehringer Ingelheim Company Information
- 6.11.2 Boehringer Ingelheim Business Overview
- 6.11.3 Boehringer Ingelheim Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Boehringer Ingelheim Drugs for Asthma and COPD Product Portfolio
- 6.11.5 Boehringer Ingelheim Recent Developments
- 6.12 Beximco
- 6.12.1 Beximco Company Information
- 6.12.2 Beximco Business Overview
- 6.12.3 Beximco Drugs for Asthma and COPD Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Beximco Drugs for Asthma and COPD Product Portfolio
- 6.12.5 Beximco Recent Developments
7 North America
- 7.1 North America Drugs for Asthma and COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 7.3 North America Drugs for Asthma and COPD Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Drugs for Asthma and COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 8.3 Europe Drugs for Asthma and COPD Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for Asthma and COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Drugs for Asthma and COPD Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Drugs for Asthma and COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 10.3 South America Drugs for Asthma and COPD Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for Asthma and COPD Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Drugs for Asthma and COPD Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst